Skip to main
ATOS
ATOS logo

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc is making notable advancements in the development of Z-endoxifen for breast cancer, which has demonstrated promising efficacy in both ESR1 mutant and wild-type patients, suggesting potential differentiation in a competitive oral SERD market. The encouraging results from various clinical trials, including significant improvements in progression-free survival (PFS) for CDK4/6i naive patients, enhance the company's strategic positioning in the neoadjuvant and preventive treatment settings. Furthermore, the company's robust pipeline, which includes COVID-19 therapeutics AT-H201 and AT-301, adds potential upside and diversification to its financial outlook, thus reflecting positively on its overall market prospects.

Bears say

Atossa Therapeutics faces significant operational and financial risks, including potential safety signals and lower than expected efficacy from its clinical programs, which could adversely affect development timelines and market competitiveness. The company anticipates requiring approximately $275 million in additional financing through 2037, projecting a cash runway only into the second half of 2026, thereby raising concerns about liquidity and funding stability. Furthermore, the risk of delisting if share prices fall below $1 compounds the uncertainty around Atossa's market positioning and long-term viability, potentially undermining investor confidence.

Atossa Genetics (ATOS) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.